A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as
Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are
Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant